{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:20:48Z","timestamp":1788481248778,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s13555-022-00687-0","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T07:02:44Z","timestamp":1644908564000},"page":"787-800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17"],"prefix":"10.1007","volume":"12","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"St\u00e5hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Nunez Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"687_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00242","author":"B Polese","year":"2020","unstructured":"Polese B, Zhang H, Thurairajah B, King IL. Innate lymphocytes in psoriasis. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00242.","journal-title":"Front Immunol"},{"key":"687_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.743180.","journal-title":"Front Med (Lausanne)"},{"key":"687_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018. https:\/\/doi.org\/10.1007\/s12016-018-8702-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"687_CR4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191397","author":"I Prinz","year":"2019","unstructured":"Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: effectors and targets in psoriasis\u2014a breakthrough in understanding and treatment. J Exp Med. 2019. https:\/\/doi.org\/10.1084\/jem.20191397.","journal-title":"J Exp Med"},{"key":"687_CR5","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S67534","author":"AS L\u00f8nnberg","year":"2014","unstructured":"L\u00f8nnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014. https:\/\/doi.org\/10.2147\/ccid.S67534.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"687_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.144","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Lebwohl MG, Bissonnette R. IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015. https:\/\/doi.org\/10.1038\/jid.2015.144.","journal-title":"J Invest Dermatol"},{"key":"687_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3742","author":"M Veldhoen","year":"2017","unstructured":"Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017. https:\/\/doi.org\/10.1038\/ni.3742.","journal-title":"Nat Immunol"},{"key":"687_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2016.05.001","author":"U Srenathan","year":"2016","unstructured":"Srenathan U, Steel K, Taams LS. IL-17+ CD8+ T\u00a0cells: differentiation, phenotype and role in inflammatory disease. Immunol Lett. 2016. https:\/\/doi.org\/10.1016\/j.imlet.2016.05.001.","journal-title":"Immunol Lett"},{"key":"687_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03240.x","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03240.x.","journal-title":"Immunology"},{"key":"687_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12560","author":"G Matsuzaki","year":"2018","unstructured":"Matsuzaki G, Umemura M. Interleukin-17 family cytokines in protective immunity against infections: role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s. Microbiol Immunol. 2018. https:\/\/doi.org\/10.1111\/1348-0421.12560.","journal-title":"Microbiol Immunol"},{"key":"687_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.04.006","author":"N Isailovic","year":"2015","unstructured":"Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015. https:\/\/doi.org\/10.1016\/j.jaut.2015.04.006.","journal-title":"J Autoimmun"},{"key":"687_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.01.016","author":"K Chen","year":"2017","unstructured":"Chen K, Kolls JK. Interluekin-17A (IL17A). Gene. 2017. https:\/\/doi.org\/10.1016\/j.gene.2017.01.016.","journal-title":"Gene"},{"key":"687_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.02.012","author":"Y Iwakura","year":"2011","unstructured":"Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.012.","journal-title":"Immunity"},{"key":"687_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143394","author":"K Bunte","year":"2019","unstructured":"Bunte K, Beikler T. Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20143394.","journal-title":"Int J Mol Sci"},{"key":"687_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347","author":"K Kamiya","year":"2019","unstructured":"Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20184347.","journal-title":"Int J Mol Sci"},{"key":"687_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497","author":"NJ Wilson","year":"2007","unstructured":"Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T\u00a0cells. Nat Immunol. 2007. https:\/\/doi.org\/10.1038\/ni1497.","journal-title":"Nat Immunol"},{"key":"687_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"687_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03017.x","author":"MM Curtis","year":"2009","unstructured":"Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009. https:\/\/doi.org\/10.1111\/j.1365-2567.2008.03017.x.","journal-title":"Immunology"},{"key":"687_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/nri3897","author":"MG Netea","year":"2015","unstructured":"Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against Candida fungal infections. Nat Rev Immunol. 2015. https:\/\/doi.org\/10.1038\/nri3897.","journal-title":"Nat Rev Immunol"},{"key":"687_CR20","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2015.1049345","author":"B Solt\u00e9sz","year":"2015","unstructured":"Solt\u00e9sz B, T\u00f3th B, Sarkadi AK, Erd\u0151s M, Mar\u00f3di L. The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans. Int Rev Immunol. 2015. https:\/\/doi.org\/10.3109\/08830185.2015.1049345.","journal-title":"Int Rev Immunol"},{"key":"687_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00684-17","author":"J Yano","year":"2018","unstructured":"Yano J, Peters BM, Noverr MC, Fidel PL. Novel mechanism behind the immunopathogenesis of vulvovaginal candidiasis: \u201cneutrophil anergy.\u201d Infection Immun. 2018. https:\/\/doi.org\/10.1128\/IAI.00684-17.","journal-title":"Infection Immun"},{"key":"687_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00469-16","author":"MA Jabra-Rizk","year":"2016","unstructured":"Jabra-Rizk MA, Kong EF, Tsui C, et al. Candida albicans pathogenesis: fitting within the host-microbe damage response framework. Infect Immun. 2016. https:\/\/doi.org\/10.1128\/iai.00469-16.","journal-title":"Infect Immun"},{"key":"687_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8020144","author":"D Rosati","year":"2020","unstructured":"Rosati D, Bruno M, Jaeger M, Ten Oever J, Netea MG. Recurrent vulvovaginal candidiasis: an immunological perspective. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8020144.","journal-title":"Microorganisms"},{"key":"687_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328358cc0b","author":"A Puel","year":"2012","unstructured":"Puel A, Cypowyj S, Mar\u00f3di L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol. 2012. https:\/\/doi.org\/10.1097\/ACI.0b013e328358cc0b.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"687_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau4594","author":"SL Gaffen","year":"2020","unstructured":"Gaffen SL, Moutsopoulos NM. Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.aau4594.","journal-title":"Sci Immunol"},{"key":"687_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040060","author":"A Verma","year":"2017","unstructured":"Verma A, Gaffen SL, Swidergall M. Innate immunity to mucosal Candida infections. J Fungi. 2017. https:\/\/doi.org\/10.3390\/jof3040060.","journal-title":"J Fungi"},{"key":"687_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9602362","author":"A Pietrzak","year":"2018","unstructured":"Pietrzak A, Grywalska E, Socha M, et al. Prevalence and possible role of Candida species in patients with psoriasis: a systematic review and meta-analysis. Mediators Inflamm. 2018. https:\/\/doi.org\/10.1155\/2018\/9602362.","journal-title":"Mediators Inflamm"},{"key":"687_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2012.05.011","author":"AA Bedair","year":"2012","unstructured":"Bedair AA, Darwazeh AM, Al-Aboosi MM. Oral Candida colonization and candidiasis in patients with psoriasis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. https:\/\/doi.org\/10.1016\/j.oooo.2012.05.011.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"687_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14263","author":"K Elsner","year":"2021","unstructured":"Elsner K, Holstein J, Hilke FJ, et al. Candida colonization in psoriasis. Exp Dermatol. 2021. https:\/\/doi.org\/10.1111\/exd.14263.","journal-title":"Exp Dermatol"},{"key":"687_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jicd.12335","author":"S Lesan","year":"2018","unstructured":"Lesan S, Toosi R, Aliakbarzadeh R, et al. Oral Candida colonization and plaque type psoriasis: is there any relationship? J Investig Clin Dent. 2018. https:\/\/doi.org\/10.1111\/jicd.12335.","journal-title":"J Investig Clin Dent"},{"key":"687_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015","author":"DM Saunte","year":"2017","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017. https:\/\/doi.org\/10.1111\/bjd.15015.","journal-title":"Br J Dermatol"},{"key":"687_CR32","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0088","author":"MP Lee","year":"2020","unstructured":"Lee MP, Wu KK, Lee EB, Wu JJ. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis. 2020. https:\/\/doi.org\/10.12788\/cutis.0088.","journal-title":"Cutis"},{"key":"687_CR33","unstructured":"European Medicines Agency. EMEA\/H\/C\/005316\u2014Bimzelx. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx. Accessed Aug, 2021."},{"key":"687_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.01894.","journal-title":"Front Immunol"},{"key":"687_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"key":"687_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"key":"687_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s0001-7310(14)70016-x","author":"Y Ling","year":"2014","unstructured":"Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014. https:\/\/doi.org\/10.1016\/s0001-7310(14)70016-x.","journal-title":"Actas Dermosifiliogr"},{"key":"687_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439","author":"A Puel","year":"2011","unstructured":"Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011. https:\/\/doi.org\/10.1126\/science.1200439.","journal-title":"Science"},{"key":"687_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021. https:\/\/doi.org\/10.1007\/s40257-020-00578-0.","journal-title":"Am J Clin Dermatol"},{"key":"687_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","author":"D Baeten","year":"2021","unstructured":"Baeten D, Adamopoulos IE. IL-23 inhibition in ankylosing spondylitis: where did it go wrong? Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.623874.","journal-title":"Front Immunol"},{"key":"687_CR41","doi-asserted-by":"publisher","DOI":"10.5414\/cp203906","author":"GG Song","year":"2021","unstructured":"Song GG, Lee YH. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: a network meta-analysis. Int J Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.5414\/cp203906.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"687_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-019-01004-6","author":"JW Hellstein","year":"2019","unstructured":"Hellstein JW, Marek CL. Candidiasis: red and white manifestations in the oral cavity. Head Neck Pathol. 2019. https:\/\/doi.org\/10.1007\/s12105-019-01004-6.","journal-title":"Head Neck Pathol"},{"key":"687_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jof6010015","author":"T Vila","year":"2020","unstructured":"Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: a disease of opportunity. J Fungi (Basel). 2020. https:\/\/doi.org\/10.3390\/jof6010015.","journal-title":"J Fungi (Basel)"},{"key":"687_CR44","first-page":"263","volume":"41","author":"RV Lalla","year":"2013","unstructured":"Lalla RV, Patton LL, Dongari-Bagtzoglou A. Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. J Calif Dent Assoc. 2013;41:263\u20138.","journal-title":"J Calif Dent Assoc"},{"key":"687_CR45","doi-asserted-by":"publisher","DOI":"10.4317\/jced.51242","author":"L Coronado-Castellote","year":"2013","unstructured":"Coronado-Castellote L, Jim\u00e9nez-Soriano Y. Clinical and microbiological diagnosis of oral candidiasis. J Clin Exp Dent. 2013. https:\/\/doi.org\/10.4317\/jced.51242.","journal-title":"J Clin Exp Dent"},{"key":"687_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2010.09.010","author":"PJ Giannini","year":"2011","unstructured":"Giannini PJ, Shetty KV. Diagnosis and management of oral candidiasis. Otolaryngol Clin North Am. 2011. https:\/\/doi.org\/10.1016\/j.otc.2010.09.010.","journal-title":"Otolaryngol Clin North Am"},{"key":"687_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.2017.886","author":"MAO Lewis","year":"2017","unstructured":"Lewis MAO, Williams DW. Diagnosis and management of oral candidosis. Br Dent J. 2017. https:\/\/doi.org\/10.1038\/sj.bdj.2017.886.","journal-title":"Br Dent J"},{"key":"687_CR48","doi-asserted-by":"publisher","DOI":"10.1067\/moe.2003.44","author":"J Barbeau","year":"2003","unstructured":"Barbeau J, S\u00e9guin J, Goulet JP, et al. Reassessing the presence of Candida albicans in denture-related stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003. https:\/\/doi.org\/10.1067\/moe.2003.44.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"687_CR49","unstructured":"Centers for Disease Control and Prevention. Candida infections of the mouth, throat, and esophagus. 2021. https:\/\/www.cdc.gov\/fungal\/diseases\/candidiasis\/thrush\/index.html. Accessed Sept, 2021."},{"key":"687_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1834-7819.2010.01226.x","author":"MS Thomas","year":"2010","unstructured":"Thomas MS, Parolia A, Kundabala M, Vikram M. Asthma and oral health: a review. Aust Dent J. 2010. https:\/\/doi.org\/10.1111\/j.1834-7819.2010.01226.x.","journal-title":"Aust Dent J"},{"key":"687_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00191-2","author":"WA Kennedy","year":"2000","unstructured":"Kennedy WA, Laurier C, Gautrin D, et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epidemiol. 2000. https:\/\/doi.org\/10.1016\/S0895-4356(99)00191-2.","journal-title":"J Clin Epidemiol"},{"key":"687_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/adj.12335","author":"M Mun","year":"2016","unstructured":"Mun M, Yap T, Alnuaimi AD, Adams GG, McCullough MJ. Oral candidal carriage in asymptomatic patients. Aust Dent J. 2016. https:\/\/doi.org\/10.1111\/adj.12335.","journal-title":"Aust Dent J"},{"key":"687_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013073","author":"Y Kawashita","year":"2018","unstructured":"Kawashita Y, Funahara M, Yoshimatsu M, et al. A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer: is topical steroid therapy a risk factor for oral candidiasis? Medicine (Baltimore). 2018. https:\/\/doi.org\/10.1097\/md.0000000000013073.","journal-title":"Medicine (Baltimore)"},{"key":"687_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/iai.72.4.1956-1963.2004","author":"A Chattopadhyay","year":"2004","unstructured":"Chattopadhyay A, Gray LR, Patton LL, et al. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004. https:\/\/doi.org\/10.1128\/iai.72.4.1956-1963.2004.","journal-title":"Infect Immun"},{"key":"687_CR55","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9290.107384","author":"P Krishnan","year":"2012","unstructured":"Krishnan P. Fungal infections of the oral mucosa. Indian J Dent Res. 2012. https:\/\/doi.org\/10.4103\/0970-9290.107384.","journal-title":"Indian J Dent Res"},{"key":"687_CR56","doi-asserted-by":"publisher","DOI":"10.4317\/jced.51798","author":"C Garcia-Cuesta","year":"2014","unstructured":"Garcia-Cuesta C, Sarrion-P\u00e9rez MG, Bag\u00e1n JV. Current treatment of oral candidiasis: a literature review. J Clin Exp Dent. 2014. https:\/\/doi.org\/10.4317\/jced.51798.","journal-title":"J Clin Exp Dent"},{"key":"687_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1834-7819.2010.01198.x","author":"C Farah","year":"2010","unstructured":"Farah C, Lynch N, McCullough M. Oral fungal infections: an update for the general practitioner. Aust Dent J. 2010. https:\/\/doi.org\/10.1111\/j.1834-7819.2010.01198.x.","journal-title":"Aust Dent J"},{"key":"687_CR58","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2013.54.1.160","author":"JH Choi","year":"2013","unstructured":"Choi JH, Lee CG, Lim YJ, Kang HW, Lim CY, Choi JS. Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. Yonsei Med J. 2013. https:\/\/doi.org\/10.3349\/ymj.2013.54.1.160.","journal-title":"Yonsei Med J"},{"key":"687_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doy094","author":"P Hoversten","year":"2018","unstructured":"Hoversten P, Kamboj AK, Katzka DA. Infections of the esophagus: an update on risk factors, diagnosis, and management. Dis Esophagus. 2018. https:\/\/doi.org\/10.1093\/dote\/doy094.","journal-title":"Dis Esophagus"},{"key":"687_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3585136","author":"AA Mohamed","year":"2019","unstructured":"Mohamed AA, Lu X-L, Mounmin FA. Diagnosis and treatment of esophageal Candidiasis: current updates. Can J Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1155\/2019\/3585136.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"687_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"key":"687_CR62","unstructured":"The National Institute for Healthcare Excellence (NICE). How should I manage oral candidiasis in a person aged 16 years or older who is not immunocompromised? In: CKS health topics A to Z. 2021. https:\/\/cks.nice.org.uk\/topics\/candida-oral\/management\/adults-young-people-not-immunocompromised\/. Accessed Aug, 2021."},{"key":"687_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003940.pub3","author":"ED Pienaar","year":"2010","unstructured":"Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.CD003940.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"687_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/0163-4453(90)90646-p","author":"CL Leen","year":"1990","unstructured":"Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect. 1990. https:\/\/doi.org\/10.1016\/0163-4453(90)90646-p.","journal-title":"J Infect"},{"key":"687_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400120096018","author":"DA Stevens","year":"1991","unstructured":"Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991. https:\/\/doi.org\/10.1001\/archinte.1991.00400120096018.","journal-title":"Arch Intern Med"},{"key":"687_CR66","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1993.tb121784.x","author":"DJ Marriott","year":"1993","unstructured":"Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust. 1993. https:\/\/doi.org\/10.5694\/j.1326-5377.1993.tb121784.x.","journal-title":"Med J Aust"},{"key":"687_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf101","author":"JL Pagani","year":"2002","unstructured":"Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother. 2002. https:\/\/doi.org\/10.1093\/jac\/dkf101.","journal-title":"J Antimicrob Chemother"},{"key":"687_CR68","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-9-199705010-00003","author":"P Schuman","year":"1997","unstructured":"Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med. 1997. https:\/\/doi.org\/10.7326\/0003-4819-126-9-199705010-00003.","journal-title":"Ann Intern Med"},{"key":"687_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(98)00137-5","author":"SG Revankar","year":"1998","unstructured":"Revankar SG, Kirkpatrick WR, McAtee RK, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998. https:\/\/doi.org\/10.1016\/s0002-9343(98)00137-5.","journal-title":"Am J Med"},{"key":"687_CR70","doi-asserted-by":"publisher","DOI":"10.1086\/497373","author":"M Goldman","year":"2005","unstructured":"Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323\/Mycoses Study Group Study 40. Clin Infect Dis. 2005. https:\/\/doi.org\/10.1086\/497373.","journal-title":"Clin Infect Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00687-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:00:53Z","timestamp":1647946853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00687-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}